Sildenafil Therapy for Interferon-β-1a-Induced Pulmonary Arterial Hypertension: A Case Report
Authors:
- Sergio CaravitaSCSergio Caravita
- Maria Beatrice SecchiMSMaria Beatrice Secchi
- Sheng Chin WuSWSheng Chin Wu
- Simona PieriniSPSimona Pierini
- Anita PaggiAPAnita Paggi
- 1 January 2011
- journal article
- case report
- Published by S. Karger AG in Cardiology
- Vol. 120 (4) , 187-189
Abstract
Interferon (IFN) therapy is nowadays widely used in clinical practice. In the literature, there are very few reports of the association between IFN therapy and pulmonary arterial hypertension (PAH), and current guidelines do not mention IFNs as a risk factor for PAH. We describe a patient with multiple sclerosis who developed severe PAH after treatment with IFN-β-1a and the clinical response to sildenafil. Furthermore, we stress the need to further investigate the link between IFNs and PAH.Keywords
This publication has 5 references indexed in Scilit:
- Irreversible Pulmonary Hypertension Associated with the use of Interferon Alpha for Chronic Hepatitis CDigestive Diseases and Sciences, 2010
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case reportMultiple Sclerosis Journal, 2009
- Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanomaCancer, 2008
- Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case reportCardiovascular Ultrasound, 2005